Definitive Contract 75A50124C00033
Award Date
9/30/24
Potential Completion Date
12/31/35
Potential Value
$268M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
Switzerland
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $135,127,180.73 definitive, cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Basilea Pharmaceutica International Ltd, doing business as Basilea Pharmaceutica International SA, for the advanced development of the antibiotic ceftobiprole. The contract supports Basilea's work on a new class of antibiotics targeting the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of the...
<p>This is a federal contract award valued at $237,994,127.86, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Hoffmann-La Roche Inc. The contract is for the "COMBATING MULTI-DRUG RESISTANCE AND ADDRESSING EMERGING BACTERIAL THREATS: DISCOVERY, CLINICAL DEVEL" program, with a period of performance through September 30, 2027. The contract is a definitive, cost-no-fee contract and does not have a set-aside designation.</p>
This is a $155,749,792.00 definitive cost-sharing contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Melinta Therapeutics, LLC, a for-profit limited liability company and manufacturer of goods. The purpose of this contract is to 1) advance the development of two antibiotics for use in the pediatric population for the treatment of serious bacterial infections where multidrug-resistant organisms are common, and 2) develop antibiotics...
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, for the clinical development of a CRISPR-Cas3 phage cocktail to treat recurrent urinary tract infections caused by Escherichia coli, including antimicrobial and multi-drug resistant strains. The contract has a ceiling value of $91,817,550.73 and a completion...
This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, Massachusetts. The contract is to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement seeking proposals to develop...
<p>This is a $323,554,976.00 Firm Fixed Price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Paratek Pharmaceuticals, Inc. for the development of an antibiotic to treat a biothreat indication. The contract has an ultimate completion date of December 17, 2029 and was awarded on December 18, 2019. This contract is not associated with a set-aside program.</p>
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses...
This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $26,427,820.00 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Revagenix Inc. The contract is for the advanced development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. This contract was awarded under a Broad Agency Announcement (BAA) solicitation that sought proposals for research and development of vaccines, therapeutics, and diagnostics...